The Gaudium IVF IPO open date is February 20, 2026, and the IPO will close on February 24, 2026. The Gaudium IVF IPO is a book-building issue. The company will raise approximately ₹[.] crore through the IPO, which includes a fresh issue of ₹[.] crore and an offer for sale of up to 94,93,700 equity shares with a face value of ₹5.
The Gaudium IVF IPO price band is ₹[.] to ₹[.] per share. The retail quota is 35%, QIB 50%, and HNI 15%. The Gaudium IVF IPO will be listed on the BSE and NSE on February 27, 2026. The allotment date for the Gaudium IVF IPO is February 25, 2026.
The company reported revenue of ₹70.96 crore in 2025, compared to ₹48.15 crore in 2024. The company reported a profit of ₹19.13 crore in 2025, compared to a profit of ₹10.32 crore in 2024. According to financials, IPO investors should apply for the long term in IPOs.
Table of Contents
Gaudium IVF & Women Health About
Key Performance Indicators (KPI)
Peer Comparison (Financial Performance)
Gaudium IVF & Women Health Lead Manager(s)
Gaudium IVF & Women Health Address
Gaudium IVF & Women Health Registrar
Gaudium IVF & Women Health
February 20, 2026 – February 24, 2026
| GMP Rumors * | ₹0 |
|---|---|
| Price | ₹0 - ₹0 |
| Lot size | 0 |
| Issue size | - |
| Allotment | Feb 25, 2026 |
| Listing | Feb 27, 2026 |
Gaudium IVF & Women Health About
IPO Details
| Total Issue Size | 2,08,86,200 shares (aggregating up to ₹* Cr) |
| Fresh Issue | 1,13,92,500 shares (aggregating up to ₹* Cr) |
| Offer For Sale | 94,93,700 shares (aggregating up to ₹* Cr) |
| Face Value | ₹5/- Per Share |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE,BSE |
| Share Holding Pre Issue | 6,13,94,384 shares |
| Share Holding Post Issue | 7,27,86,884 shares |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not less than 50% of the Net Issue |
| Retail Shares Offered | Not more than 35% of the Net Issue |
| NII Shares Offered | Not more than 15% of the Net Issue |
Key Performance Indicators (KPI)
| KPI | Sep-25 | Fiscal-25 | FiscaL-24 | Fiscal-23 |
|---|---|---|---|---|
| ROE | 21.25% | 41.31% | 38.23% | 59.51% |
| ROCE | 21.03% | 39.37% | 38.74% | 54.40% |
| EPS (BASIC) | 2.04 | 3.12 | 1.68 | 2.20 |
Company Financial (In ₹Crore)
| Period Ended | Sep-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| NET Worth | 58.85 | 46.3 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.6 | 26 | 21.74 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
Peer Comparison (Valuation)
| Company | P/E (x) | CMP*(₹) | Face value *(₹) |
|---|---|---|---|
| Gaudium IVF and Women Health Limited | 5.00 | ||
| Progyny Inc | 41.56 | 2099.98 | $0.0001 |
| Inspire IVF Public Company Limited | 11.43 | 1.99 | THB 0.05 |
SOURCE:RHP, Financials of company are based on restated financial statement for fiscal 2025, Financials of peers are based on fiscal 2024 and currency conversion rate is as on December 31, 2024. Closing price of Progyny Inc. was taken from NASDAQ and closing price of Inspire IVF Public Company Limited was taken from The Stock exchange of Thailand as on January 17, 2025 respectively, converted to Indian rupee based on exchange rate of $/₹ of 80.6232 as on December 31, 2024 and THB/₹2.4878 as on December 31, 2024 respectively.
Peer Comparison (Financial Performance)
| Company | NAV/Share (₹) | RoNW (%) | EPS (Basic) (₹) |
|---|---|---|---|
| Gaudium IVF and Women Health Limited | 7.54 | 41.71 | 3.12 |
| Progyny Inc | 394.20 | 12.90 | 50.52 |
| Inspire IVF Public Company Limited | 4.34 | 3.97 | 0.17 |
About Company
Incorporated in March 2015, Gaudium IVF and Women Health Limited is engaged in providing In Vitro Fertilization (IVF) and women’s healthcare services across India through a hub-and-spoke model.
Our company is engaged in IVF (In vitro fertilization) treatment in India and has grown into several states with Huband spoke model over the years. Gaudium IVF is founded by our Promoter Dr. Manika Khanna, a specialist with advanced training in gynecological endoscopic surgery from Kiel, Germany, and in Gynaec Endoscopy from Melbourne IVF Gujarat Private Limited. The company operates 30+ locations, which comprises of 7 hubs (centers) and 28 spokes (company has entered into a strategic alliance with Spokes i.e Infertility Expert to achieve the mutual goal of spreading awareness about ART and IVF treatment). Our treatments include In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI) and ovulation induction, all our treatment is carefully designed to address a variety of infertility challenges for both male and female.
The company operates over 30 locations, including 7 hub centres and 28 spoke centres, expanding its reach through a strategic alliance with infertility experts to promote awareness of ART and IVF treatments.
It caters to both domestic and international patients from countries such as Canada, the UK, the USA, Kenya, South Africa, and Oman.
Centres are located in key cities including Delhi (Janakpuri & Kailash Colony), Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore.
The company offers specialized fertility services such as IVF, ICSI, IUI, ovulation induction, egg freezing, laser-assisted embryo implantation, along with treatment for PCOD/PCOS, endometriosis, high-risk pregnancy management, and advanced male infertility procedures.
Facilities are equipped with next-generation INTEGRA Ti labs for advanced ICSI procedures.
Strength
Patient-Centric Pricing Approach: The Company adopts package-based treatments, bundled services, and installment schemes to make fertility care affordable for middle-income groups. Transparent pricing and flexible financing options enhance patient trust and expand the customer base.
Strong Brand Positioning & Trust Creation: The Company focuses on awareness campaigns, patient education, and testimonials to reduce stigma and strengthen its brand credibility. Accreditation from recognized medical associations and adherence to ethical practices further enhance reputation and reliability.
Focus on Medical Tourism: Leveraging India’s cost advantage, the Company attracts international patients through multilingual support, concierge services, and global collaborations. Strategic tie-ups with overseas agencies and hospitals support a steady inflow of foreign patients.
Weakness
Operational & Medical Risks in Fertility Services: The Company operates in fertility treatments such as IVF, IUI, ICSI, and egg freezing, which involve medical, operational, legal, and reputational risks. Any failure to maintain quality healthcare standards could adversely affect its reputation, business prospects, and financial performance.
Related Party Transactions & Potential Conflicts: The Company has entered into and may continue to enter into related party transactions, including loans, advances, and guarantees. Such arrangements may give rise to potential conflicts of interest.
Dependence on Limited Embryologists: The Company’s operations across seven centers rely heavily on five embryologists. Any inability to retain or attract qualified embryologists could adversely impact operations, financial condition, and growth.
You can visit our website, newipo.info, for information on IPOs, the stock market, gold, crypto investments, and more. Our staff carefully research all the information on this site and provide it to you. This can help investors in various ways.
Gaudium IVF & Women Health Lead Manager(s)
- Sarthi Capital Advisors Private Limited
Gaudium IVF & Women Health Address
Gaudium IVF & Women Health Ltd.
Address
B1/51,
Janak Puri,
B-1,New Delhi, New Delhi, 110058
011-4885 8585
E-Mail: compliance@gaudiumivfcentre.com
Website:https://www.gaudiumivfcentre.com/
Gaudium IVF & Women Health Registrar
Bigshare Services Pvt Ltd
Phone: +912262638200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
Address: Bigshare Services Pvt Ltd 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis,Makwana Road, Marol, Andheri(E), Mumbai - 400 059